Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast biopsy & localization cases in Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 122 | 7,700 | 24% |
| 2020 | 116 | 6,995 | 28% |
| 2021 | 128 | 7,818 | 33% |
| 2022 | 130 | 7,382 | 37% |
| 2023 | 133 | 7,599 | 40% |
| 2024 | 130 | 7,399 | 42% |
| 2025 from claims | – | 8,008 7,349–8,472 | 43% |
| 2026 forecast | – | 8,273 7,279–9,546 | 44% |
| 2027 forecast | – | 8,500 7,267–10,130 | 44% |
| 2028 forecast | – | 8,733 7,287–10,693 | 45% |
| 2029 forecast | – | 8,971 7,327–11,251 | 46% |
| 2030 forecast | – | 9,215 7,382–11,808 | 46% |
Image-guided breast biopsy and marker/localization placement. Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 21% of the cases CMS names in Virginia; 76 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 80% hospital outpatient, 20% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 245 | 16,085−0.7%/yr | −0.7%/yr | 7.7 | 39% | 18,600 in 2030+2.5%/yr |
| Texas | 203 | 11,818−2.4%/yr | −2.4%/yr | 5.9 | 24% | 13,700 in 2030+2.5%/yr |
| North Carolina | 133 | 8,308−3%/yr | −3%/yr | 9.0 | 45% | 8,490 in 2030+0.4%/yr |
| Georgia | 103 | 5,906−2.9%/yr | −2.9%/yr | 7.3 | 17% | 6,640 in 2030+2%/yr |
| Maryland | 79 | 5,089−2.2%/yr | −2.2%/yr | 6.0 | 73% | 5,630 in 2030+1.7%/yr |
| Tennessee | 81 | 4,468−4.7%/yr | −4.7%/yr | 6.8 | 31% | 4,740 in 2030+1%/yr |
| South Carolina | 68 | 3,858−2.4%/yr | −2.4%/yr | 6.0 | 11% | 4,310 in 2030+1.8%/yr |
| Kentucky | 49 | 3,005−2.2%/yr | −2.2%/yr | 7.0 | 6% | 3,430 in 2030+2.2%/yr |
| Louisiana | 36 | 2,413−3.9%/yr | −3.9%/yr | 6.3 | 14% | 2,390 in 2030−0.2%/yr |
| Oklahoma | 56 | 2,408+1%/yr | +1%/yr | 5.2 | 2% | 2,580 in 2030+1.1%/yr |
| Alabama | 36 | 2,322−3.8%/yr | −3.8%/yr | 5.7 | 10% | 2,460 in 2030+1%/yr |
| Arkansas | 39 | 2,201−3.4%/yr | −3.4%/yr | 6.2 | 36% | 2,190 in 2030−0.1%/yr |
| District of Columbia | 28 | 1,896+2.5%/yr | +2.5%/yr | 31.6 | 69% | 2,250 in 2030+2.9%/yr |
| Mississippi | 36 | 1,779−6.5%/yr | −6.5%/yr | 5.0 | 22% | 1,620 in 2030−1.5%/yr |
| Delaware | 19 | 1,063−4.7%/yr | −4.7%/yr | 6.5 | 26% | 1,140 in 2030+1.1%/yr |
| West Virginia | 16 | 949−6.7%/yr | −6.7%/yr | 4.9 | 8% | 890 in 2030−1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Tumor & fibroid embolization | 12 | 902+21%/yr | +21%/yr | 0.91.6× | 55% | 2,310 in 2030+17%/yr |
| Tumor ablation | 1 | 278+2.6%/yr | +2.6%/yr | 0.30.8× | 0% | 470 in 2030+9%/yr |
Breast biopsy & localization in every state, and its device makers · Every procedure market in Virginia · Every state · Compare with Florida
Pulse Biosciences leads with 71% of company spending on these surgeons in 2025, +71 pts on 2024.
In 2025, 17 companies reported engagement with Virginia’s surgeons worth $617K in consulting, speaking, meals and travel tied to these products, about $4,747 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.